| Publisher’s Note: Join Fierce Biotech Editors and industry leaders at the Fierce Biotech Summit to network and gain exclusive insights. Don’t miss out — register now! |
Today’s Big NewsSep 11, 2024 |
|
Still Time to Shine! Submission deadline for the Fierce Life Sciences Innovation Awards have been extended to September 12. Click to submit your entry and learn more about what winner's will receive. 
|
|
| By James Waldron Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage trials, the pharma’s head of metabolism R&D has told Fierce Biotech. |
|
|
|
By James Waldron GSK’s attempt to develop the first vaccine for herpes simplex virus has ended in failure, leaving the race open for the likes of Moderna and BioNTech. |
By Nick Paul Taylor BridgeBio Pharma is slashing its gene therapy budget and pulling back from the modality after seeing the results of a phase 1/2 clinical trial. CEO Neil Kumar, Ph.D., said the data “are not yet transformational,” driving BridgeBio to shift its focus to other drug candidates and ways to treat disease. |
By Nick Paul Taylor Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential for further reductions in longer trials. |
|
Partner with us for vaccine manufacturing that expertly integrates novel analytical and process-related technologies with your program's unique needs, ensuring efficient tech transfer and rapid scaling. Grow with us. 
|
|
By Darren Incorvaia Roche’s R&D is moving on up. The pharma giant has opened two new high-rises in Basel, Switzerland, according to a Sept. 10 release. The facility is named the Pharma Research and Early Development (pRED) Center, and houses about 1,000 state-of-the-art laboratory and office workplaces. |
By Fraiser Kansteiner In a lawsuit filed Friday, AbbVie argued that BeiGene “enticed and encouraged” former AbbVie scientist Huaqing Liu to jump ship and share proprietary information on AbbVie’s development program for BTK degrader drugs in blood cancers. |
By Darren Incorvaia Carisma Therapeutics has been working for years to develop cell therapies using macrophages, immune cells that are better at attacking solid tumors than the T cells that currently dominate the industry. In a partnership with Moderna, now expanded to two undisclosed autoimmune targets, the biotech hopes to seriously simplify cell therapy by bypassing the need to culture patient cells out of the body. |
By Kevin Dunleavy Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria, Sanofi and Regeneron have presented data from a phase 3 trial that could help push the megablockbuster across the finish line in the indication. |
By Conor Hale The agency's researchers will conduct experiments to measure the amounts of metals that may leech out of tampons and enter the body under everyday use. |
By Paige Minemyer UnitedHealth Group's Optum Rx will join its peers in the big three pharmacy benefit managers by pulling Humira from some of its preferred formularies, according to a report from Reuters. |
By Conor Hale The tech giant plans to add sleep apnea detection to its Apple Watch as well as bring long-anticipated over-the-counter hearing aid tech to its AirPods. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," we’re looking at what goes into manufacturing and supply of flu vaccines. |
|
|---|
|
|
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
